We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Ocular Therapeutix (OCUL - Free Report) shares ended the last trading session 24.2% higher at $5.13. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.7% loss over the past four weeks.
The company's shares surged as it recently reported positive interim data from a phase I study, evaluating its candidate OTX-TKI for wet age-related macular degeneration (wet AMD) and other retinal diseases. The company’s AMD candidate exhibited stable and sustained best corrected visual acuity (BCVA) and central subfield thickness (CSFT) compared with Regeneron’s Eylea (aflibercept). Ocular intends to progress the AMD candidate to a phase II study in the third quarter of 2023, post an FDA discussion. It also plans to initiate a phase I study of OTX-TKI for diabetic retinopathy, during the same time frame.
This biotechnology company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $14.71 million, up 21% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Ocular Therapeutix, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on OCUL going forward to see if this recent jump can turn into more strength down the road.
Ocular Therapeutix is part of the Zacks Medical - Drugs industry. Collegium Pharmaceutical (COLL - Free Report) , another stock in the same industry, closed the last trading session 2.3% lower at $15.84. COLL has returned -7.7% in the past month.
Collegium Pharmaceutical's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.25. Compared to the company's year-ago EPS, this represents a change of +468.2%. Collegium Pharmaceutical currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?
Ocular Therapeutix (OCUL - Free Report) shares ended the last trading session 24.2% higher at $5.13. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.7% loss over the past four weeks.
The company's shares surged as it recently reported positive interim data from a phase I study, evaluating its candidate OTX-TKI for wet age-related macular degeneration (wet AMD) and other retinal diseases. The company’s AMD candidate exhibited stable and sustained best corrected visual acuity (BCVA) and central subfield thickness (CSFT) compared with Regeneron’s Eylea (aflibercept). Ocular intends to progress the AMD candidate to a phase II study in the third quarter of 2023, post an FDA discussion. It also plans to initiate a phase I study of OTX-TKI for diabetic retinopathy, during the same time frame.
This biotechnology company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $14.71 million, up 21% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Ocular Therapeutix, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on OCUL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Ocular Therapeutix is part of the Zacks Medical - Drugs industry. Collegium Pharmaceutical (COLL - Free Report) , another stock in the same industry, closed the last trading session 2.3% lower at $15.84. COLL has returned -7.7% in the past month.
Collegium Pharmaceutical's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.25. Compared to the company's year-ago EPS, this represents a change of +468.2%. Collegium Pharmaceutical currently boasts a Zacks Rank of #3 (Hold).